Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5752W HIGH $2.44
Volume
40.49 K
Value Traded
55.70 K
Short % Float
7.65%
-3.61%Week
-21.79%1 Month
-54.14%3 Month
-65.06%6 Month
-84.71%5 Year
-92.15%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
24.14 M
EPS (TTM)
-0.12
P/E Ratio
-
Ent. Value
17.61 M
Total Shares
41.13 M
Float Shares
31.95 M
Insiders
22.31%
Institutions
5.53%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BYSI Catalyst Timeline
Dated clinical, regulatory and corporate events for BeyondSpring, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BeyondSpring, Inc.
521Total events
4Upcoming
125Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
TBD
T3Enrollment Update
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 50
▲Fast Track DesignationPlinabulinFiledDesignation
FDA grants Fast Track designation to Plinabulin plus docetaxel in post-ICI non-squamous NSCLC
advanced or metastatic non-squamous NSCLC without actionable genomic alterations following progression on ICI and chemotherapysource ↗
▲Partnership / LicenseCorporate
BeyondSpring enters definitive agreement with Biolin to sell BeyondSpring Ltd. and fund China portion of DUBLIN-4
non-squamous NSCLCsource ↗
●R&D DayPresentation
BeyondSpring management hosts conference call and webcast to discuss FDA Fast Track and strategic transaction
●Management ChangeCorporate
Min Qiu appointed CEO, Dr. Jiangwen (Jen) Majeti appointed Vice Chairman, Na Li appointed CFO
◆Oral PresentationPlinabulinFiledPresentation
Updated efficacy and safety data from Phase 2 303 Study presented at ASCO 2026
metastatic non-small cell lung cancer (NSCLC) after progression on first-line immune checkpoint inhibitor therapysource ↗
▲Topline ReadoutPlinabulinFiledClinical Data
Topline results: median PFS 7.0 months, median DoR 9.3 months, DCR 79.5%, ORR 18.2%, 12-month OS rate 78.1%, 24-month OS rate 58.0%
metastatic non-small cell lung cancer (NSCLC) after progression on first-line immune checkpoint inhibitor therapysource ↗
▲Oral PresentationPlinabulinFiledPresentation
Updated efficacy and safety results from Phase 2 303 Study presented at ASCO 2026
metastatic NSCLC post-ICIsource ↗
◆Poster PresentationPlinabulinFiledPresentation
Poster presentation of Study 303 at 2026 ASCO Annual Meeting
2L/3L NSCLCsource ↗
◆Oral PresentationPlinabulinFiledPresentation
AACR 2026 oral presentation of preclinical data on Plinabulin combined with ADCs
cancer (ADC combination)source ↗
▲Preclinical PoCPlinabulinFiledPreclinical
Preclinical proof-of-concept data for Plinabulin + ADC combinations
cancer (ADC combination)source ↗
◆Poster PresentationPlinabulinFiledPresentation
Poster presentation at AACR 2026: Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor
cancersource ↗
▲Oral PresentationPlinabulinFiledPresentation
Preclinical data presented at AACR 2026 showing Plinabulin enhances ADC efficacy and tolerability
ADC combinations (preclinical)source ↗
◆Oral PresentationPlinabulinFiledPresentation
Presentation at Immuno-Oncology 360° Conference on Plinabulin
cancersource ↗
▲Oral PresentationPlinabulinFiledPresentation
Phase 2 Study 303 data for Plinabulin, docetaxel and PD-1 inhibitor presented at ASCO 2026
NSCLC progressed following PD-1 inhibitor treatmentsource ↗
◆Oral PresentationPlinabulinFiledPresentation
ESMO Asia 2025 presentation of Asian subset results from DUBLIN-3
EGFR wild-type non-small cell lung cancersource ↗
▲Topline ReadoutPlinabulinFiledClinical Data
Asian subset topline results: OS improvement in ITT and non-squamous subgroup
EGFR wild-type non-small cell lung cancersource ↗
▲Oral PresentationPlinabulinFiledPresentation
Post-hoc analyses of DUBLIN-3 presented at NACLC 2025
non-squamous EGFR wild-type NSCLCsource ↗
▲Oral PresentationPlinabulinFiledPresentation
Updated data presented at IASLC North America and ESMO Asia
non-squamous EGFR wild-type NSCLCsource ↗
▲IND ClearanceST-01156IND
IND clearance from US FDA and China NMPA for RBM39 molecular-glue degrader ST-01156
Ewing sarcoma and other RBM39-dependent cancerssource ↗
▲Full ResultsPlinabulinFiledClinical Data
Publication of DUBLIN-3 trial results in The Lancet Respiratory Medicine
NSCLCsource ↗
●Oral PresentationPlinabulinFiledPresentation
Presentation at SITC conference on Plinabulin's potential after checkpoint inhibitors
NSCLC and other cancerssource ↗
▲IND ClearanceST-01156IND
FDA clearance to enter clinical trials for ST-01156
aggressive cancers including Ewing Sarcoma and KRAS-driven tumorssource ↗
▲Full ResultsPlinabulinFiledClinical Data
Publication of Dublin-3 Phase 3 trial results in LANCET Respiratory Medicine
NSCLCsource ↗
●Development Candidate NominationPreclinical
SEED targeting IND candidate status for Tau degrader project
neurodegeneration (Tau)source ↗
▲PublicationPlinabulinFiledPresentation
Publication in Med (Cell Press) of Plinabulin-driven dendritic cell maturation and tumor response after prior checkpoint inhibitor failure
multiple cancer types refractory or relapsed on prior ICI therapysource ↗
●IND SubmissionRBM39IND
IND submission for RBM39 molecular-glue degrader on track for mid-2025
Ewing Sarcomasource ↗
◆Poster PresentationPlinabulinFiledPresentation
Poster presentation of Phase 2 data for Plinabulin + pembrolizumab + docetaxel in 2L/3L NSCLC at 2025 ASCO
metastatic non-small cell lung cancer (NSCLC)source ↗
◆Poster PresentationPlinabulinFiledPresentation
Poster presentation at 2025 ASCO Annual Meeting
2L/3L NSCLCsource ↗
▲Enrollment CompletePlinabulinFiledTrial
Enrollment completed for 303 Study (47 patients)
metastatic non-small cell lung cancer (NSCLC)source ↗
▲Full ResultsPlinabulinFiledClinical Data
Phase 3 data published in The Lancet Respiratory Medicine showing statistically significant survival benefit
second- and third-line non-small cell lung cancer (EGFR wild-type)source ↗
▲Oral PresentationPlinabulinFiledPresentation
Oral presentation at IO 360° conference showing early efficacy for Plinabulin combinations
metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapysource ↗
▲Equity OfferingCorporate
Sale of portion of Series A-1 Preferred Shares of SEED Therapeutics for $35.4 million
▲Full ResultsPlinabulinFiledClinical Data
DUBLIN-3 results published in The Lancet Respiratory Medicine
EGFR wild-type NSCLCsource ↗
▲Oral PresentationPlinabulinFiledPresentation
Plinabulin + PD-1 inhibitor + radiation data presented at SITC 2025 and published in Med 2025
eight tumor types resistant to checkpoint inhibitorssource ↗
◆Management ChangeCorporate
Appointment of Dr. Bill Desmarais as CFO and CBO of SEED Therapeutics
●Timing GuidancePlinabulinFiledPresentation
Prepare for NMPA submission
second- and third-line non-small cell lung cancer (EGFR wild-type)source ↗
Past FDA Catalysts and PDUFA Decisions
How BYSI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-31 | Plinabulin (Plin) + Docetaxel + Pembrolizumab | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 50%
Micro Cap(rank 328 of 656)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Plinabulin Small moleculeNCT07361484 | Non-Small Cell Lung Cancer | Phase 3 | NOT YET_RECRUITING | 442 | Dec 1, 2029 | ||||||
| ST-01156 Small moleculeNCT07197554 | Advanced Solid Tumors | Phase 1 | RECRUITING | 171 | Dec 31, 2029 | ||||||
| Plinabulin Small moleculeCompletedNCT04345900 | Chemotherapy-induced Neutropenia | Phase 3 | COMPLETED | 275 | Apr 20, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every BYSI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pembrolizumab plus Plinabulin and docetaxel BreakthroughPriorityFast Track | metastatic NSCLC | Phase 2 | 2026-06-02 | Median PFS: 7.0 months; Median Do R: 9.3 months; DCR: 79.5%; 12 Month OS Rate: 78.1%; 24 Month OS Rate: 58.0%; Confirmed ORR: 18.2%Read More | BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Majeti JiangwenDirector | Grant/Award | 100,000 100,000 held | $0.00 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BYSI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 0 % | 20.00 K | 10.83 K |
BYSI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BYSI ranks across every disease it competes in
Competitive Position is a premium feature
See how BYSI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBYSI News
BYSI▼ -31%on this news
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
BeyondSpring has received FDA Fast Track designation for Plinabulin combined with docetaxel in treating advanced non-squamous NSCLC. The company also announced a strategic transaction to fund the China portion of the Phase 3 DUBLIN-4 trial, which aims to enroll 442 patients globally. This non-dilutive funding approach is expected to enhance clinical development efficiency.
Read more →BYSI▼ -15.2%on this news
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Inc. reported positive financial results for Q2 2026, highlighting encouraging clinical data for Plinabulin in metastatic NSCLC. The company announced a leadership transition aimed at advancing the DUBLIN-4 program, which focuses on improving survival rates in patients who have progressed on first-line therapy. Additionally, preclinical findings presented at AACR 2026 support Plinabulin's potential as a combination therapy with ADCs.
Read more →BYSIBeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
BeyondSpring, a clinical-stage biopharmaceutical company, has announced a leadership transition effective July 1, 2026, aimed at executing its confirmatory DUBLIN-4 program for Plinabulin. Dr. Min Qiu has been appointed as CEO with a mandate to drive this pivotal study alongside a strengthened Board led by Dr. Lan Huang, who remains Chairman. The new leadership structure is designed to ensure focused execution and strategic governance, supporting BeyondSpring's goal of establishing Plinabulin as a new standard of care for a significant patient population. The company also emphasizes a solid intellectual property portfolio protecting its assets through 2041.
Read more →BYSIBeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
BeyondSpring Inc. presented updated results from its Phase 2 study of pembrolizumab combined with Plinabulin and docetaxel for metastatic NSCLC patients who progressed after prior immune checkpoint inhibitor therapy. The study demonstrated a median progression-free survival of 7.0 months and a 12-month overall survival rate of 78.1%. The treatment showed good tolerability and a high disease control rate of 79.5%.
Read more →BYSIBeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
BeyondSpring Inc. announced a poster presentation for Study 303 at the 2026 ASCO Annual Meeting. This Phase 2 study evaluates the combination of plinabulin, docetaxel, and pembrolizumab in patients with metastatic NSCLC who have progressed after prior treatments. The presentation is scheduled for May 31, 2026, in Chicago.
Read more →BYSIBeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Inc. reported its financial results for Q1 2026, highlighting advancements in its cancer treatment pipeline, particularly with Plinabulin, which shows promise as a backbone agent in antibody-drug conjugate therapies. The company also announced the advancement of ST-01156, a molecular glue degrader, into clinical development. Despite these advancements, the company faced a net loss of $2.4 million for the quarter.
Read more →BYSI▼ -6.3%on this news
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
BeyondSpring Inc. (NASDAQ: BYSI) presented new preclinical data at the AACR 2026 meeting showing that Plinabulin can significantly improve the efficacy and safety profiles of antibody-drug conjugates (ADCs). The results indicate that Plinabulin enhances complete tumor response rates while simultaneously reducing neutropenia, a common side effect that limits ADC treatment. This positions Plinabulin as a promising candidate for combination therapies, potentially transforming the landscape of cancer treatment. The findings support ongoing and future clinical trials that aim to validate these benefits across various cancer indications.
Read more →BYSIBeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
BeyondSpring Inc. announced a poster presentation at the 2026 AACR Annual Meeting, scheduled for April 21, 2026. The presentation will focus on the efficacy of Plinabulin in enhancing the effects of topoisomerase inhibitor-based antibody-drug conjugates. The event will take place in San Diego, California, highlighting advancements in cancer treatment.
Read more →BYSIBeyondSpring Files 2025 Annual Report on Form 10-K
BeyondSpring Inc. has filed its annual report on Form 10-K for the fiscal year ending December 31, 2025. This report includes the company's audited consolidated financial statements and is accessible on the SEC's website. The company continues to focus on developing innovative therapies for cancer treatment, particularly its lead asset, Plinabulin.
Read more →BYSIBeyondSpring Reports 2025 Year-End Financial Results
BeyondSpring reported positive financial results for 2025, highlighting significant progress in its lead program, Plinabulin, which demonstrated a survival benefit in a Phase 3 study for NSCLC. The company plans to advance a confirmatory Phase 3 trial, DUBLIN-4, and has strengthened its financial position with new funding. SEED Therapeutics also made strides with its first clinical program.
Read more →BYSIBeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
BeyondSpring Inc. will participate in the Immuno-Oncology 360° Conference 2026, scheduled for February 10-12 in Boston, MA. Dr. Lan Huang, the company's CEO, will present on Plinabulin, emphasizing its role in overcoming PD-1/L1 resistance. The presentation aims to showcase Plinabulin's unique mechanism and clinical development strategy.
Read more →BYSIBeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
BeyondSpring Inc. announced promising results from the Asian subset of its Phase 3 DUBLIN-3 trial, showing that Plinabulin combined with docetaxel significantly improves overall survival in patients with EGFR wild-type non-small cell lung cancer. This combination achieved a median overall survival of 10.8 months compared to 8.8 months for docetaxel alone, particularly benefiting non-squamous patients. The trial's findings highlight Plinabulin's ability to enhance chemotherapy tolerability and reduce the incidence of severe side effects. These results support the potential of Plinabulin as a new treatment standard for NSCLC.
Read more →BYSI▲ +7.9%on this newsshared move
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
BeyondSpring announced positive post-hoc analyses from the DUBLIN-3 Phase 3 study, indicating that Plinabulin combined with docetaxel offers significant survival benefits for patients with EGFR wild-type non-squamous NSCLC who have progressed after anti-PD-(L)1 therapy. The findings were presented at the 2025 NACLC and highlight the potential of Plinabulin to address unmet medical needs in this patient population. A global Phase 3 DUBLIN-4 trial is planned to further support these findings.
Read more →BYSIBeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
BeyondSpring Inc. reported its Q3 2025 financial results, highlighting the progress of its lead asset, Plinabulin, which has shown a favorable safety profile in over 700 patients. The company also announced IND clearance for its RBM39 molecular-glue degrader. The results from the Phase 3 DUBLIN-3 trial indicate potential for Plinabulin to enhance cancer treatment standards. However, the company faces risks related to financing and regulatory approvals.
Read more →BYSIBeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
BeyondSpring Inc. reported its Q2 2025 financial results, highlighting significant clinical advancements and a strategic leadership appointment. The company emphasized the potential of Plinabulin, a first-in-class cancer treatment, in improving outcomes for patients with non-small cell lung cancer. Additionally, SEED Therapeutics, in which BeyondSpring holds a stake, received FDA clearance for its innovative cancer-targeting agent.
Read more →BYSIBeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
BeyondSpring Inc. announced the publication of a human clinical study in Med, demonstrating that Plinabulin, in combination with radiation and checkpoint inhibitors, can induce dendritic cell maturation and tumor responses in patients who previously failed ICI therapy. The study highlights the potential of Plinabulin in treating various cancer types and identifies a biomarker for patient selection. The results suggest a promising avenue for overcoming ICI resistance.
Read more →BYSIBeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
BeyondSpring presented interim Phase 2 data at the 2025 ASCO Annual Meeting, showing promising results for Plinabulin combined with pembrolizumab and docetaxel in treating metastatic NSCLC after progression on first-line therapies. The study involved 47 patients, highlighting the potential of Plinabulin to overcome resistance to checkpoint inhibitors. The findings suggest improved survival rates and reduced severe neutropenia compared to existing treatments.
Read more →BYSI▼ -5.7%on this news
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
BeyondSpring Inc. announced a poster presentation for the 303 Study at the 2025 ASCO Annual Meeting. This study evaluates the efficacy of Plinabulin combined with docetaxel and pembrolizumab for patients with metastatic NSCLC who have progressed after prior treatments. The presentation will occur from May 30 to June 3 in Chicago, IL.
Read more →BYSIBeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
BeyondSpring Inc. has announced its financial results for Q1 2025, highlighting the early efficacy of Plinabulin in treating metastatic NSCLC and Hodgkin lymphoma. The company is also progressing towards an IND filing for its RBM39 degrader aimed at Ewing sarcoma. However, BeyondSpring reported a loss from continuing operations that increased compared to the previous year, attributed to rising research and administrative expenses. Overall, while there are promising developments in clinical efficacy, the financial outlook remains challenging.
Read more →About BeyondSpring, Inc.
Headquarters100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NJ, 07932
BIOPHARMAWATCH ELITE PLUS
Trade the next BYSI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime